Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Department of Gynaecology, Division of Gynaecology and Obstetrics, University Medical Centre, 1000 Ljubljana, Slovenia.
Medicina (Kaunas). 2022 Feb 23;58(3):339. doi: 10.3390/medicina58030339.
Persistent infection with human papillomavirus (HPV) causes almost all cervical precancerous lesions and cancers. Bivalent, quadrivalent, and nonavalent HPV vaccines effectively prevent high-grade cervical intraepithelial neoplasia (CIN3). The effectiveness of HPV vaccination against CIN3 is 97-100% in HPV-naïve populations and 44-61% in the overall population. Although HPV vaccination has substantially reduced the incidence of cervical cancers, several cases of precancerous cervical lesions in HPV-vaccinated patients have been reported. We report the clinical case of a 19-year-old woman whose first Pap smear was diagnosed as a high-grade squamous intraepithelial lesion (HSIL) after quadrivalent HPV vaccination. Colposcopy and cervical biopsy were performed, revealing HSIL/CIN3. Our multidisciplinary team decided to take a conservative approach with follow-up visits with cervical biopsies of this young patient. After six months, spontaneous regression of high-grade cervical dysplasia was observed. Although HPV immunization has shown to be extremely effective in preventing a high proportion of cervical precancerous lesions and cervical cancers, HPV vaccines do not protect against all oncogenic high-risk HPV genotypes. Consequently, healthcare providers must encourage HPV-vaccinated women to still regularly attend national cervical screening programs.
人乳头瘤病毒(HPV)持续感染几乎会引起所有宫颈癌前病变和癌症。二价、四价和九价 HPV 疫苗可有效预防高级别宫颈上皮内瘤变(CIN3)。HPV 疫苗对 HPV 未感染人群的 CIN3 有效性为 97-100%,对总体人群的有效性为 44-61%。虽然 HPV 疫苗接种大大降低了宫颈癌的发病率,但仍有少数 HPV 疫苗接种患者出现宫颈癌前病变。我们报告了一例 19 岁女性的临床病例,她在接种四价 HPV 疫苗后首次巴氏涂片检查诊断为高级别鳞状上皮内病变(HSIL)。进行了阴道镜检查和宫颈活检,结果显示为 HSIL/CIN3。我们的多学科团队决定对这位年轻患者采取保守治疗方法,定期进行宫颈活检随访。六个月后,观察到高级别宫颈发育不良的自发消退。虽然 HPV 免疫接种已被证明在预防很大比例的宫颈癌前病变和宫颈癌方面非常有效,但 HPV 疫苗并不能预防所有致癌的高危型 HPV 基因型。因此,医疗保健提供者必须鼓励 HPV 疫苗接种的女性仍定期参加国家宫颈癌筛查计划。